

REMARKS/ARGUMENTS

In the Office Action dated December 28, 2005, claims 1-6, 11-14, 29-34 and 36-45 were rejected under the doctrine of obviousness type double patenting over Claims 1-6 and 11-12 of United States Patent No. 6,660,024 in view of United States Patent No. 6,375,615. No other grounds for rejection were stated in the Office Action.

Enclosed herewith is a Terminal Disclaimer relating to United States Patent No. 6,375,615. This Terminal Disclaimer overcomes the stated obviousness type double patenting rejection.

Also, by the foregoing amendment, a minor typographical error has been corrected in claim 23.

Conclusion

Applicant believes all the pending claims 1-6, 11-14, 29-34 and 36-45 are in condition for allowance and should be passed to issue. The Commissioner is hereby authorized to charge the large entity fee for the enclosed Terminal Disclaimer as well as any additional fees which may be required under 37 C.F.R. 1.17, or credit any overpayment, to Deposit Account No. 01-2525. If the Examiner feels that a telephone conference would in any way expedite the prosecution of the application, please do not hesitate to call the undersigned at telephone (707) 566-1746.

Respectfully submitted,

/Michael J. Jaro, Reg. No. 34,472/
Michael J. Jaro
Registration No. 34,472
Attorney for Applicant

Medtronic Vascular, Inc.
3576 Unocal Place
Santa Rosa, CA 95403
Facsimile No.: (707) 543-5420